Investing.com - Anebulo Pharmaceuticals reported on Friday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Anebulo Pharmaceuticals announced earnings per share of $-0.1 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.075 on revenue of $0.00.
Anebulo Pharmaceuticals shares are down 20.63% from the beginning of the year , still down 53.08% from its 52 week high of $7.89 set on Tuesday, February 1, 2022. They are outperforming the Nasdaq which is down 22.93% year to date.
Anebulo Pharmaceuticals shares lost 7.27% in intra-day trade the report.
Anebulo Pharmaceuticals follows other major Healthcare sector earnings this month
Anebulo Pharmaceuticals's report follows an earnings beat by Medtronic on Tuesday, August 23, 2022, who reported EPS of $1.13 on revenue of $7.37B, compared to forecasts EPS of $1.12 on revenue of $7.22B.
Agilent Technologies had beat expectations on Tuesday, August 16, 2022 with third quarter EPS of $1.34 on revenue of $1.72B, compared to forecast for EPS of $1.2 on revenue of $1.64B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar